Cebranopadol, a Novel Potent Analgesic: Review of Clinical Studies Conducted Across Multiple Types of Pain including Chronic Lower Back Bain, Acute Pain, Diabetic Peripheral Neuropathy, and Cancer Pain (PAINWeek 2022) - Sep 19, 2022 - Abstract #20; "Across the 8 trials, patients were randomized to receive 25-1000μg/day of cebranopadol by mouth or a control including , placebo, morphine sulfate sustained release (SR), tapentadol prolonged release (PR), morphine sulfate PR, pregabalin, or oxycodone controlled release (CR), for a duration of 2 days to 15 weeks... Cebranopadol has demonstrated efficacy across a variety of pain types, and when considered along with safety and abuse potential data may serve as a much-needed treatment option for patients with moderate to severe pain. Learning Objectives: Upon completion, participant will be able to describe the clinical studies used to study the efficacy and safety of cebranopadol. Upon completion, participant will be able to identify the pain types that cebranopadol has demonstrated efficacy in Upon completion, participant will be able to describe the safety of cebranopadol in patients"
Clinical • Review • Back Pain • CNS Disorders • Musculoskeletal Pain • Pain • Peripheral Neuropathic Pain
|
|
David Fam, PharmD; Antonio Pardo, MD; James Hackworth, PhD
|